Rein Therapeutics Inc. (RNTX) Stock Overview
Explore Rein Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Rein Therapeutics Inc. (RNTX)
Key Financials
Key Financials
Market Cap
27.2M
P/E Ratio
-0.48
EPS (TTM)
$-1.77
ROE
-2.58%
RNTX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Rein Therapeutics Inc. (RNTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 46.66, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.60.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.48 and a market capitalization of 27.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.